FTSE MIB
33.781,52 +74,31 (+0,22%) Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
81,12 +0,29 (+0,36%) Bitcoin EUR
57.490,90 +621,91 (+1,09%)
NeuroPace, Inc. (NPCE)
Dopo ore:
| Chiusura precedente | 6,69 |
| Aperto | 6,77 |
| Denaro | 6,68 x 200 |
| Domanda | 6,77 x 100 |
| Min-Max giorno | 6,65 - 6,81 |
| Intervallo di 52 settimane | 3,91 - 18,15 |
| Volume | |
| Media Volume | 115.318 |
| Capitalizzazione | 193,034M |
| Beta (mensile su 5 anni) | 1,80 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,18 |
| Prossima data utili | 06 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 17,25 |
GlobeNewswireNeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York. A live webcast of the Cantor Fitzgerald discussion can be accessed through the Events & Presentations
- GlobeNewswire
NeuroPace to Participate in Upcoming Investor Conferences
- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21st Annual Global Healthcare Conference - - Lake Street Capital Markets 7th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences: Management will host 1x1 meetings at the Wells
- GlobeNewswire
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increased to $59-$61 million, up from $52-54 million Cash burn reduced to $4 million in the second quarter of 2023, relative to $9.8 million in the first quarter of 2023 MOUNTAIN VIEW, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results
